Feeding the epigenome: EZH2 as a metabolic integrator of cell fate in development and cancer

2026/07/23 by Suraiya Anjum Ansari, Bright Starling Emerald
Biochemistry, Genetics and Molecular Biology · #Cancer, Hypoxia, and Metabolism #Epigenetics and DNA Methylation #RNA modifications and cancer

paper · doi:10.1016/j.mam.2026.101499

openalex publication_date 2026/07/23 · openalex created_date 2026/07/24 · openalex updated_date 2026/07/30

Abstract

, and other metabolic intermediates. Consequently, disruption of this finely tuned regulatory network can contribute to developmental abnormalities, metabolic dysfunction, and oncogenesis. In this review, we examine the molecular mechanisms governing EZH2 regulation and discuss how metabolic control of EZH2 shapes chromatin dynamics, cell fate decisions, and disease pathogenesis. Elucidating how metabolic signals modulate EZH2 activity will advance our understanding of development and disease while uncovering potential therapeutic opportunities to target metabolism-driven epigenetic dysregulation.

Citations

• Elevated expression of fatty acid synthase and nuclear localization of carnitine palmitoyltransferase 1C are common among human gliomas
• NAD+ and sirtuins in aging and disease
• The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways
• Metabolic reprogramming and cancer progression
• The hallmarks of cancer metabolism: Still emerging